The Role of Nitric Oxide in BCG Treatment for Bladder Cancer
Author Information
Author(s): OT Jansson, E Morcos, L Brundin, JON Lundberg, J Adolfsson, M Söderhill, NP Wiklund
Primary Institution: Karolinska Hospital
Hypothesis
Is nitric oxide involved in the anti-tumour activity of bacillus Calmette-Guerin (BCG) in bladder cancer treatment?
Conclusion
Nitric oxide production is significantly increased in the bladder following BCG treatment, suggesting it plays a key role in the anti-tumour effects of this therapy.
Supporting Evidence
- Patients treated with BCG showed a 30 times higher production of nitric oxide in the bladder.
- Calcium-dependent nitric oxide synthase activity increased fourfold in BCG-treated patients compared to normal controls.
- NO donors exhibited cytotoxic effects on bladder cancer cell lines.
Takeaway
This study found that a substance called nitric oxide increases a lot when patients receive BCG treatment for bladder cancer, which might help fight the cancer.
Methodology
The study involved measuring nitric oxide synthase activity and nitric oxide production in bladder tissue from patients treated with BCG.
Limitations
The study had a small sample size and did not assess the long-term effects of nitric oxide on cancer progression.
Participant Demographics
Patients included 8 treated with BCG for recurrent superficial bladder cancer and 12 with recurrent papillary bladder cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website